



Herlev og Gentofte Hospital  
Hud- og Allergiafdelingen  
Kildegårdsvej 28  
2900 Hellerup  
Att.: Alexander Egeberg

Ballerup, 15 November 2017

**Agreement on support to establish a database comprising data on the entire Danish population.**

Pfizer is very pleased to confirm that it will provide support to the above-mentioned project and has therefore entered into this Agreement.

The support will be given to Hud og Allergiafdelingen (hereafter the Recipient) and is approved by Claus Zachariae, Consultant, Head of Department on behalf of Herlev og Gentofte Hospital.

The purpose of the activity is to establish a database comprising data on the entire Danish population.

In this database, specific clinical parameters and patient-reported outcomes are obtained from a subset of 30,000 sampled adults. A specific aim of the present database is to generate a cohort of subjects with information on parameters that are not readily available from existing data sources in Denmark, such as but not limited to

- Smoking status, quantity and history
- Alcohol consumption, quantity and history
- Height, weight, and body-mass index
- Patient reported outcomes
  - o EQ-5D-5L (EuroQoL 5 Dimensions 5 Levels)
  - o Quality of life
  - o Itch
  - o Pain

Respondents are followed prospectively, and data are updated over time. Hence, this database will comprise novel and unique data combined and integrated with existing data sources from nationwide registries and therefore enable research in a wide variety of disease- and therapeutic areas.

The agreement shall run from 15 November 2017 to 30 November 2017.

Pfizer's financial commitment in relation to this Agreement shall be 350.000 DKK excl. VAT.  
Pfizer will not provide any non-financial support.

Furthermore the support is approved by Alexander Egeberg, MD, PhD who is responsible for the hospital account to which the funding is paid to.

The Recipient will ensure that the support is used solely for professional and scientific purposes in relation to the research project and undertakes that any surplus from the support not used in accordance herewith will be refunded.

Upon request from Pfizer the Recipient must document that the support is spend in accordance with the above-mentioned.

The Recipient undertakes the full responsibility for the execution of the research project and Pfizer disclaims every right to interfere with the execution and any other part of the research project. Furthermore the Recipient will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.

Please complete and sign the attached Payment Form and return to Pfizer as soon as possible together with the signed agreement. Please note that Pfizer will be precluded from providing you with the financial support if you do not state a CVR-number on the Payment Form.

**Disclosure**

This agreement will be available on Pfizer's webpage ([www.pfizer.dk](http://www.pfizer.dk)) when the support is granted and for a period of 2 years thereafter.

**Data Privacy**

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland are protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.

You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.

The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's anti-corruption provisions (Appendix A).

By signing this agreement, the Recipient confirms to have read and understood Pfizer's policy relating to bribery and corruption pursuant to Appendix A and that the support is spend in accordance with the above mentioned terms and conditions.

We kindly ask you to return the signed agreement to Pfizer.

Date:

Signature of authorized signatory on behalf of Pfizer:

*Humma Khan*

Troels Reiche  
Country Medical Director

*(on behalf of Troels Reiche)*

*15.11.2017*

Date:

*15.11.17*

Signature of authorized signatory on behalf of Herlev og Gentofte Hospital:

*[Handwritten Signature]*

Claus Zachariae  
Consultant, Head of Department

## Appendix A – Anti-Corruption Contract Provisions

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity and, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment; and
- 1.3 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support, has used or intend[s] to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support.